Others - Outcome without intimation
Deal
Deal value₹14 Cr
Deal vs businessFundraise of ₹14.09 Cr vs TTM revenue of ₹1.0 Cr (14x TTM revenue) and Net Worth of ₹9 Cr (1.56x NW)
Size vs own revenue14.00× — oversized — in the 90-day study 20% of these fell >25%, against 4% of deals under half of revenue
Execution period—
Fundamental gradeD
AI projections
Revenue uplift (yr1 / steady)100.0% / 300.0%
EPS uplift50.0%
Upside base / bull / bear15.0% / 50.0% / -35.0%
Horizon12-24 months
Realized market record
Entry — next-day open (06 Aug 2026)₹96.9
Latest close (16 Sep 2026)₹99.2
Return since+2.4%
α vs Smallcap 250+5.2%
Positives
- Capital infusion of ₹14.09 Cr significantly expands equity capital base from ₹9 Cr to ~₹23 Cr.
- Induction of Global9 LLC as a key non-promoter shareholder holding 15.89% post-issue.
- Debt-free status provides complete balance sheet flexibility for deploying fresh capital into trading operations.
Risks
- Equity dilution of ~20-25% resulting from the allotment of 15.485 lakh new shares.
- Extremely fragile operational profile with Q4 FY26 recording zero revenue.
- Rich trailing valuation of 63.4x P/E relative to unstable fundamental earnings capacity.
- High execution uncertainty on whether new working capital can yield sustainable operating margins.
Governance flags
- Highly erratic revenue profile including a zero-revenue quarter in Q4 FY26.
- FY25 net profit of ₹2.66 Cr was almost entirely driven by non-operating income (operating profit was only ₹0.01 Cr).
Full AI brief
Executive Summary & Fundraise Context On August 5, 2026, Eforu Entertainment completed a preferential allotment of 15,48,500 equity shares at ₹91 per share, raising ₹14.09 Cr. The issue expands the capital base significantly relative to the company's existing Net Worth of ₹9 Cr (1.56x NW) and current Market Cap of ₹56 Cr (~25% equity dilution). The allotment includes promoter Amit Pankaj Vedawala (2.98L shares) and Global9 LLC (taking a 15.89% post-issue stake). ### Financial & Quality Assessment 1. Operational Base: TTM Revenue stands at just ₹1.0 Cr with TTM PAT at ₹1.0 Cr. In FY26, total revenue was ₹1.33 Cr, but Q4 FY26 recorded ₹0.0 Cr revenue and an operating loss of ₹0.23 Cr. FY25 profits were heavily distorted by non-operating items (PAT ₹2.66 Cr vs Op Profit ₹0.01 Cr). 2. Valuation: Trailing P/E of 63.4x is steep compared to the peer median P/E of 27.8x, offering minimal safety margin given the operational inconsistency. 3. Quality & Governance: Rated Fundamental Grade 'D'. While ROCE is reported at 12.5% and the company is debt-free, the total absence of revenue in Q4 FY26 highlights severe operational fragility and lack of business continuity. ### Fundraise Impact & Math - Capital Infusion: ₹14.09 Cr added to Net Worth. - Dilution: Share count increases by ~15.485 lakh shares on an estimated ~60 lakh share base (~20-25% dilution). - Revenue Ramp: Assuming the ₹14 Cr is fully deployed as working capital for trading, top-line can scale from ₹1 Cr to ₹3-5 Cr over 12-24 months. At standard trading operating margins (~8-12% core), net profit would stabilize around ₹0.4-0.6 Cr on core business, rendering current valuation rich unless non-linear growth materializes. ### Scenario Calibrations - Bull Case (+50%): Company successfully deploys funds into high-margin trading lines, scaling annual revenues to >₹8 Cr with >10% OPM. - Base Case (+15%): Moderate revenue scaling to ₹3-4 Cr with standard trading margins, offset by dilution drag and valuation compression. - Bear Case (-35%): Inability to deploy capital productively; top-line remains volatile and stock re-rates towards peer multiples (~25-30x P/E). ### Final Verdict While the cash infusion expands net worth substantially, the absence of operational scale and inconsistent financial reporting cap the multibagger potential. Rated UNLIKELY with a multibagger score of 35/100.
Analysis as of 2026-08-05 (price ₹93.27) ·
AI research, not investment advice.
FollowTelegram
